Acute Basophilic Leukemia: Recent Molecular and Diagnostic Update

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Acute basophilic leukemia (ABL) is an uncommon acute leukemia subtype.
• Clinical presentation is often linked to hyper-histaminemia and bone marrow failure due to leukemic blast infiltration.
• Leukemic blasts typically express myeloid markers (CD13, CD33) and basophil-specific markers (CD123, CD203c, CD11b), while KIT (CD117) and monocytic markers are usually negative.

Purpose of the Study:

• To investigate the role of the MYB-GATA1 fusion gene in the pathogenesis of acute basophilic leukemia.
• To understand the molecular mechanisms underlying basophilic differentiation and immaturity in ABL.

Main Methods:

• Analysis of leukemic blast immunophenotypes, including myeloid and basophil-specific markers.
• Investigation of the t(X;6) (p11; q23) translocation and its resulting MYB-GATA1 fusion gene.
• Assessment of gene expression patterns, including MYB, GATA1, NTRK1, and IL1RL1, in relation to the MYB-GATA1 fusion.

Main Results:

• The MYB-GATA1 fusion gene, resulting from t(X;6) translocation, has been identified in sporadic ABL cases.
• Expression of MYB-GATA1 in hematopoietic cells promotes granulocytic lineage commitment and inhibits early differentiation.
• MYB-GATA1 expression leads to increased CD34, CD33, CD117, CD203c, and FcRI expression, indicating immaturity and basophilic characteristics.
• MYB and MYB-GATA1 directly activate NTRK1 and IL1RL1 transcription, contributing to basophilic skewing.

Conclusions:

• The MYB-GATA1 fusion gene is a key driver in a subset of acute basophilic leukemia, promoting immature basophilic phenotypes.
• Understanding the molecular pathways involving MYB-GATA1 offers potential therapeutic targets for ABL.